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Based on the structure of AAP, a novel anti-thrombotic peptide from snake venom which we discovered
in our previous study, more than 60 compounds were designed and synthesized. One of these termed as
LX0702 exhibited stronger anti-platelet aggregation activity than AAP. This study aims to investigate the
effects of LX0702 on anti-thrombotic formation and its underlying mechanism. We found that LX0702
inhibited platelet aggregation induced by ADP, thrombin and collagen in a dose dependent manner, with
IC50 values of 49.90 ± 2.03, 50.65 ± 0.34 and 83.90 ± 2.06 mM, respectively. It also inhibited thrombus
formation in the rat arterio-venous shunt model. In addition, the effect of LX0702 on hemostasis system
was tested. Compared to control saline, bleeding time was not prolonged. Furthermore, the ELISA
revealed that LX0702 inhibited ﬁbrinogen binding with GPIIb/IIIa in a dose dependent manner with an
IC50 value of 1.26 ± 0.13 mM. These ﬁndings clearly demonstrate that LX0702 has anti-platelet/anti-
thrombotic effects without increased bleeding risk. Therefore it might be developed into an effective
drug for the prevention or treatment of thrombotic diseases.
© 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological
Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
Cardiovascular diseases (CVDs) are the leading cause of mor-
tality and morbidity in the modern era (1,2). The proximal cause of
CVDs is intravascular thrombosis formation, which mostly results
from platelet activation, adhesion, granule contents release and
platelet aggregation (3e6).
GPIIb/IIIa, is a two subunit platelet-speciﬁc integrin receptor,
which is most abundant adhesion/aggregation receptor on the
surface of platelets with a number of 60,000e80,000 per platelet
(7). In its resting state GPIIb/IIIa has a bent conformation while an
extended conformation during its active state (8). In the active
state, the afﬁnity of GPIIb/IIIa for ﬁbrinogen is high. Fibrinogen,
with multiple adhesive sites, crosslinks adjacent platelets through
GPIIb/IIIa to form a platelet plug. The resulting plug provides a site
for the assembly of coagulation protein complexes that convert
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d/4.0/).Thus, GPIIb/IIIa receptor antagonists, preventing the interaction of
GPIIb/IIIa receptors with ﬁbrinogen, are considered as the most
potent antiplatelet agents (9e11).
Currently, three agents (abciximab, eptiﬁbatide, and tiroﬁban),
targeting GPIIb/IIIa have been approved for human use by FDA (12).
They have shown clinical effectiveness when used as adjunctive
therapy for preventing ischemic complications percutaneous cor-
onary interventions and various other clinical conditions (13).
However, they also have some limitations, such as the induction of
thrombocytopenia (14,15) and increased risk of bleeding (16).
We have previously derived a peptide from snake venom named
AAP. This peptide can inhibit the binding of ﬁbrinogen to GPIIb/IIIa
and thrombosis formation with a low bleeding risk (17). To further
explore its structure and effectiveness,we synthesized a series of AAP
derivatives guided by structural and energetic considerations.
LX0702, one of the derivatives, was more potent than AAP in inhib-
iting platelet aggregation, so we selected it for further evaluation.
In the present study, we investigated the in vivo and in vitro
pharmacological activity of LX0702, and found that LX0702 inhibited
the platelet aggregation induced by ADP, thrombin and collagen.
Furthermore, it inhibited thrombosis formation in a rat arterio-
venous shunt model, whereas it did not prolong the tail bleedingnese Pharmacological Society. This is an open access article under the CC BY-NC-ND
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it showeddirect inhibitionofﬁbrinogenbindingwithGPIIb/IIIa. These
ﬁndingsunderscored that LX0702canplayaneffective role as ananti-
platelet agent for the prevention or treatment of thrombotic diseases.
2. Materials and methods
2.1. Reagents
LX0702 and AAP were received from Dr. Zhiyu Li (China Phar-
maceutical University, China) and were dissolved in DMSO as a
stock solution, stored at 20 C. Aspirin, ADP, thrombin, collagen
type I, heparin, human ﬁbrinogen, apyrase, PGE1 and anti-mouse
IgG-conjugated alkaline phosphatase were purchased from Sigma
(St.Louis, MO, USA). Puriﬁed human platelet GPIIb/IIIa receptor was
obtained from Enzyme Research Laboratories (Southbend, IN, USA).
All of the other chemicals were analytical grade. 0.2% of DMSO in
vehicle was used as a control solution.
2.2. Animals
SpragueeDawley rats (male, 260e280 g), New Zealand rabbits
(male, 2.0e2.5 kg) and ICR mice (both sexes, 18e22 g) were pur-
chased fromNanjingQinglongshanAnimal Center (Jiangsuprovince,
China). They were kept in a temperature-controlled environment
(22 ± 2 C), with 55 ± 5% relative humidity and a 12-h light-dark
cycle, and fed with standard chow, for at least 1 week before any
manipulations. All protocols were approved by the Committee on
the Ethics of Animal Experiments of China Pharmaceutical Univer-
sity (Nanjing, China) and conformed to the National Institutes of
Health Guideline for Care and Use of Laboratory Animals.
Platelets were isolated as described by previous methods
(18,19). Brieﬂy, blood was withdrawn from the carotid artery of
rabbit after the local anesthesiawith urethane (800mg/kg, i.v.), and
collected into tubes containing 3.8% sodium citrate (1:9 dilution,
citrate/blood, v/v). PRP was prepared by centrifugation for 20 min
at 900 rpm. Platelets were pelleted at 1200 rpm for 15 min in the
presence of 0.5 U/mL apyrase and 1 mM prostaglandin E (PGE)1, and
washed twice in platelet-washing buffer (36 mM citric acid, 5 mM
glucose, 5 mM KCl, 1 mM MgCl2, 103 mM NaCl, pH 6.5). Washed
platelets were resuspended in modiﬁed Tyrode buffer (137 mM
NaCl, 12 mM NaHCO3, 2 mM KCl, 0.34 mM Na2HPO4, 1 mM MgCl2,
bovine serum albumin (BSA) 0.35 g/L, 5.5 mM glucose, and 5 mM
HEPES, pH 7.4). 2 mM CaCl2 and 0.4 mg/mL ﬁbrinogen were added
immediately before the experiments. Platelet concentration was
adjusted to 3  108 platelets/ml.
2.3. Antiplatelet aggregation assay
In vitro platelet aggregation was measured by the turbidimetric
method (20), with a minor modiﬁcation, using a four-channel
aggregometer (Beijing Pulisheng Science Instrument Company,
China). Brieﬂy, 270 ml platelets were incubated in the cuvette with
20 ml of sample solution at the concentration of 200, 100, 50 and
10 mM at 37 C for 5 min (aspirin: 30 min), and 0.2% of DMSO in
saline was used as a control group. Platelet aggregation was
induced by the addition of 10 ml of ADP (10 mM), thrombin (0.5 U/
ml) or collagen (10 mg/ml) in saline after incubation. The maximum
aggregation rate was recorded for 5 min with continuous stirring.
The light transmittancewas calibratedwithmodiﬁed Tyrode buffer.
2.4. Fibrinogen/GPIIb/IIIa ELISA
The ﬁbrinogen/GPIIb/IIIa solid-phase assay was performed ac-
cording to a previous method (21) but with a minor modiﬁcation.The 96-well microplates (Corning Incorporated, Corning, NY, USA)
were coated with the human ﬁbrinogen (10 mg/ml) diluted in 0.1 M
sodium carbonate, at a pH of 9.5 and 4 C temperature overnight.
After washing with TACTS (20 mM Tris, 0.15 M NaCl, pH 7.5, 2 mM
CaCl2, 0.05% Tween 20), the plate was blocked with 1% bovine
serum albumin (BSA, Beyotime, China) in TACTS for 1 h. Puriﬁed
human platelet GPIIb/IIIa receptor (20 mg/ml) and a series of sam-
ples diluted in TACTS containing 0.5% BSA were added. After incu-
bation for 2 h at 37 C, the plate was washed in TACTS followed by
addition of mouse anti-human integrin b3 antibody (1:2,000, Mil-
lipore, Bedford, MA, USA) in TACTS containing 0.5% BSA. After 1 h
incubation at 37 C, wells were washed (TACTS) and anti-mouse
IgG-conjugated alkaline phosphatase (1:2,000, A3562; Sigma) in
TACTS containing 0.5% BSA was added to the wells. The ﬁnal
washing was performed after 1 h incubation. Stabilized p-nitro-
phenyl phosphate liquid substrate solution (Amresco, USA) was
added and incubated for about 30min, and 3MNaOHwas added to
stop the reaction. The absorbance was estimated at 405 nm.2.5. Arterio-venous shunt model in rats
The antithrombotic activity of LX0702 was determined in a rat
arterio-venous shunt thrombosis model as described by Sperzel
and Huetter (22) with a minor modiﬁcation. Male SpragueeDawley
rats (260e280 g) were anesthetized with urethane (800 mg/kg,
i.p.). Then the left jugular vein and right carotid arterywere isolated
and linked by a shunt catheter (American Health &Medical Supply
International Corp, Scarsdale, NY, USA), which was composed of
three parts including two 4 cm polyethylene (PE) 50 catheters and a
8 cm PE60 catheter. A 12-cm long silk thread (0.25 mm diameter)
folded into a double string was in the middle of PE60 catheter to
induce thrombosis. The shunt catheter was ﬁlled with heparin sa-
line solution (0.5 mg/ml). Samples (5 ml/kg) were injected through
caudal vein. Fifteen min after the venous injection (1 h after
injecting aspirin), the shunt was opened for 15min and then closed.
The silk thread was removed from the PE60 catheter. The wet
thrombus attached in the silk thread was weighed immediately.
The dry thrombus weight was measured after dried at 60 C for 2 h.
The thrombus weight was deﬁned as the wet weight or the dry
weight minus the corresponding weight of the silk thread. Aspirin,
the classical anti-platelet drug, was used as a positive control.2.6. Bleeding time assay
The bleeding time was determined using a modiﬁed tail cutting
method, as described previously (23). Rats were anesthetized by i.p.
administration of urethane (1 g/kg) after administration of LX0702,
AAP or aspirin (5 ml/kg, i.v), a distal 2 mm segment of the tail was
amputated with a scalpel. The tail was immediately immersed in a
40 ml falcon tube containing 0.9% saline pre-warmed in a water
bath at 37 C. The bleeding timewasmeasured from themoment of
transection until bleeding stopped completely. Observation was
stopped at 15 min, if bleeding did not cease, and longer time was
classiﬁed as 15 min. Aspirin was used as a positive drug. At the end
of experiment, rats were killed by anesthesia overdose.2.7. Statistical analysis
Data was analyzed by GraphPad PRISM 6.0 statistical software
(San Diego, CA). All numerical results are presented as
mean ± S.E.M. Statistical differences were analyzed by two -way
analysis of variance (ANOVA) followed by Bonferroni post hoc test,
as appropriate. Statistical signiﬁcance was considered as P < 0.05.
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3.1. Inhibition of platelet aggregation in vitro
As shown in Fig. 1(BeD), LX0702 inhibited the platelet ag-
gregation induced by ADP (10 mM), thrombin (0.5 U/ml) and
collagen (10 mg/ml) in a dose-dependent manner (10e200 mM),
and the IC50 values were 49.90 ± 2.03, 50.65 ± 0.34 and
83.90 ± 2.06 mM, respectively. With the increase in ADP con-
centration, the inhibitory effect of LX0702 did not signiﬁcantly
reduce (not shown). When the concentration of LX0702 was
10 mM, the platelet aggregation was 43.92 ± 1.94%, and when its
concentration was 200 mM, the platelet aggregation was
7.28 ± 0.15%.Fig. 1. A) Chemical structure of AAP (left) and LX0702 (right). B) Effect of LX0702 and AAP o
LX0702 and AAP were pre-incubated with washed platelets for 5 min at 37 C (aspirin: 30 m
Effect of LX0702 and AAP on platelet aggregation induced by thrombin. Four concentrations
for 5 min at 37 C prior to the addition of thrombin (0.5 U/ml). Data is presented as mean ±
Four concentrations (10, 50, 100 and 200 mM) of LX0702 and AAP were pre-incubated with
presented as mean ± S.E.M. (n ¼ 3). E) Effect of Aspirin, LX0702 and AAP (200 mM) on pla
presented as mean ± S.E.M. (n ¼ 3). ***P < 0.001, ****P < 0.0001 compared with control grTo compare the anti-platelet aggregation activity of LX0702
with aspirin and AAP, we conducted experiment where platelet
aggregation was induced by ADP. At the similar concentration of
100 mM, LX0702 had showed higher anti-platelet aggregation ac-
tivity than that of aspirin or AAP (Fig 1E). The aggregation ratios of
LX0702, aspirin and AAP were 11.37 ± 0.83%, 23.32 ± 1.24% and
21.60 ± 1.57%, respectively. These ﬁndings demonstrated that
LX0702 indeed has the capacity to attenuate in vitro platelet ag-
gregation, and it is stronger than that of aspirin or AAP.
3.2. Inhibition of ﬁbrinogen binding with GPIIb/IIIa
Inhibition of ﬁbrinogen bindingwith GPIIb/IIIawasmeasured by
the solid-phase ﬁbrinogen/GPIIb/IIIa ELISA. As shown in Fig. 2,n platelet aggregation induced by ADP. Four concentrations (10, 50, 100 and 200 mM) of
in) prior to the addition of ADP (10 mM). Data is presented as mean ± S.E.M. (n ¼ 3). C)
(10, 50, 100 and 200 mM) of LX0702 and AAP were pre-incubated with washed platelets
S.E.M. (n ¼ 3). D) Effect of LX0702 and AAP on platelet aggregation induced by collagen.
washed platelets for 5 min at 37 C prior to the addition of collagen (10 mg/ml). Data is
telet aggregation induced by ADP. Control group was added with 0.2% DMSO. Data is
oup, ##p < 0.01 compared with AAP-treated group and aspirin-treated group.
Fig. 2. Effect of LX0702 and AAP on the binding of ﬁbrinogenwith GPIIb/IIIa. The initial
slope of binding was measured in the absence of LX0702 (circle) and AAP (triangle)
(designated as a concentration of 10∞), and the inhibition was assessed as an OD
value at 405 nm. Each value is shown as the value obtained from individual experi-
ment (n ¼ 3).
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in a dose-dependent manner (0.1e100 mM), and the IC50 value was
1.26 ± 0.13 mM, the inhibition ability was more potent than that of
AAP at the same concentration. At the concentration of 1 mM, the
inhibition ratio of LX0702 was 48.11 ± 1.44%, and that of AAP was
20.78 ± 2.11%.3.3. Antithrombotic activity in vivo
LX0702 signiﬁcantly decreased both wet and dry thrombus
weight in a dose-dependent manner (0.5e2 mM) in the rat arterio-
venous shunt model as shown in Fig. 3. Although at the dosage of
2 mM, aspirin and AAP also attenuated thrombus weight, LX0702
comparatively exhibited a stronger antithrombotic ability.Fig. 3. Effect of LX0702 on the thrombus weights in the arterio-venous shunt model in
rats. Animals were separated into six groups, and injected with 0.2% DMSO, 2 mM AAP,
and a series of LX0702: 2, 1 and 0.5 mM (Dosing volume were 5 ml/kg). Data is pre-
sented as mean ± S.E.M. (n ¼ 6). ****P < 0.0001, **P < 0.01, *P < 0.05 compared with
control group, ##p < 0.01, #p < 0.05 compared with AAP-treated group and Aspirin-
treated group.3.4. Bleeding time evaluation in vivo
To assess the bleeding risk with LX0702, we measured LX0702-
injected SD rat bleeding time at 2-fold concentration (1, 2 and
4 mM, i.v.) for in vivo antithrombotic study. In comparison to the
control group (6.94 ± 0.59 min, n ¼ 6), as demonstrated in Fig. 4,
LX0702 did not prolong tail bleeding time. After injecting 1, 2 and
4mM of LX0702, the bleeding timewas only 7.03 ± 0.61, 7.52 ± 0.44
and 7.83 ± 0.62 min, respectively. While separate control experi-
ments revealed that aspirin signiﬁcantly and AAP slightly pro-
longed the bleeding time (Fig. 4). The difference between aspirin
and LX0702 was statistically signiﬁcant.
4. Discussion
We designed and synthesized more than 60 compounds based
on the structure of AAP (a peptide from snake venom). One of them
named LX0702 was found to be a potent anti-platelet aggregation
compound. In in vitro and in vivo experiments, we found that
LX0702 inhibited ADP, thrombin and collagen induced platelet
aggregation in a concentration-dependent manner. Furthermore, it
inhibited thrombus formation in rat arterio-venous shunt model,
and did not exhibit bleeding risk in tail cutting assay in mice. These
results indicated that LX0702 might be a promising candidate for
anti-thrombotic drug development.
Platelet agonists ADP, thrombin and collagen act on different
receptors located on the surface of platelets membrane, leading to
their activation through different signaling transduction pathways.
Results in the present study showed that, LX0702 inhibited platelet
aggregation induced by all three above mentioned inducers, which
implied that it may affect a common pathway of platelet activation.
As it is a well known fact that GP IIb/IIIa is involved in the ﬁnal
pathway of platelet aggregation (24,25), so the inhibition effect of
LX0702 was tested on it, and the results indicated that LX0702 af-
fects the binding of ﬁbrinogen with GPIIb/IIIa.
Many GPIIb/IIIa antagonists have been studied in the past
decade, where three (abciximab, eptiﬁbatide and tiroﬁban) of them
are most commonly used for preventing thrombotic diseases (25).
However, they all showed obvious bleeding risk (26e28). While inFig. 4. Effect of LX0702 on tail bleeding time in rats. Animals were separated into six
groups, and injected with 0.2% DMSO, 4 mM AAP, and a series of LX0702: 4, 2 and
1 mM (Dosing volume were 5 ml/kg). Data is presented as mean ± S.E.M. (n ¼ 6).
**P < 0.05 compared with control group, #p < 0.05 compared with aspirin-treated
group.
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rats. Compared to control, aspirin prolonged the bleeding time from
6.93 min to 10.65 min at an effective dosage, while LX0702 did not
prolong bleeding time at three different dosages (1, 2 and 4 mM).
These results indicate that LX0702 is might be a safer compound for
preventing thrombotic disease.
The potential value of any anti-thrombotic compound is not
merely decided by its efﬁcacy but safety is also a crucial factor (no
bleeding risk). For instance, efﬁcacy of aspirin is even though lower
than tiroﬁban, but due to its better safety it is been more clinically
used. According to the results, the effective dosage of LX0702 for its
anti-thrombotic effect was not as low as of tiroﬁban (data not
shown), but it was lower than aspirin. This ﬁnding that, LX0702 is
appeared to be more effective than aspirin and did not prolong
bleeding time implicated a possible application value of LX0702 in
prevention of thrombotic diseases.
All the drugs targeting GPIIb/IIIa, have shown bleeding risk
during their clinical use. Immense research has been done to
overcome this drawback. Now it is reported that three kinds of
novel compounds have been developed, which showed anti-
platelet activity by employing different strategies without any
risk of bleeding. One of them is RUC-1, it only binds to the GPIIb
subunit not to GPIIIa (29); another is a human single-chain anti-
body, it only blocks the activated form of the integrin GPIIb/IIIa
(30,31); the third one is allosteric inhibitor, it targets two residues
95e105 on the GPIIIa subunit and holds GPIIb/IIIa in the bent
conformation (32). Here, we found that LX0702 also inhibited
GPIIb/IIIa binding with ﬁbrinogen and showed a strong anti-
thrombotic action without bleeding risk, but whether or not it
uses the above three strategies, it needs to be further explored.
In this paper, we investigated the pharmacological activity of a
new compound LX0702 and found that it signiﬁcantly inhibited
thrombosis formation in rat but did not prolong the bleeding time.
These ﬁndings reinforce that LX0702 might be developed into a
candidate or drug for the prevention or treatment of thrombotic
diseases. With further understanding of the ingegrin GPIIb/IIIa and
signal pathways for platelet, such as one by Bo Shen (33) (a switch
of inside-out to outside-in signal pathway in platelet), safer and
effective drugs can be developed for human use for treatment of
thrombotic diseases.Conﬂict of interest
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